Divergent effects of first-generation and second-generation antipsychotics on cortical thickness in first-episode psychosis

Psychological Medicine

Volumn 45, Issue 3, 2015, Pages 515-527

  Ansell, B R E ^a   Dwyer, D B ^a   Wood, S J ^a,b   Bora, E ^a   Brewer, W J ^a   Proffitt, T M ^a   Velakoulis, D ^a   McGorry, P D ^a   Pantelis, C ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Antipsychotics; cortical thickness; first episode psychosis; first generation; second generation

Indexed keywords

NEUROLEPTIC AGENT;

ADOLESCENT; ADULT; AFFECTIVE DISORDERS, PSYCHOTIC; ANATOMY AND HISTOLOGY; BRAIN CORTEX; CASE CONTROL STUDY; CLASSIFICATION; DRUG EFFECTS; FEMALE; HUMAN; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; SCHIZOPHRENIA; YOUNG ADULT;

ADOLESCENT; ADULT; AFFECTIVE DISORDERS, PSYCHOTIC; ANTIPSYCHOTIC AGENTS; CASE-CONTROL STUDIES; CEREBRAL CORTEX; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; SCHIZOPHRENIA; YOUNG ADULT;

EID: 84927694090     PISSN: 00332917     EISSN: 14698978     Source Type: Journal    
DOI: 10.1017/S0033291714001652     Document Type: Article

References (64)

1. Abi-Dargham A, Laruelle M (2005). Mechanisms of action of second generation antipsychotic drugs in schizophrenia: insights from brain imaging studies. European Psychiatry 20, 15-27.
2. Aguado F, Carmona MA, Pozas E, Aguiló A, Martínez-Guijarro FJ, Alcantara S, Borrell V, Yuste R, Ibañez CF, Soriano E (2003). BDNF regulates spontaneous correlated activity at early developmental stages by increasing synaptogenesis and expression of the K+/Clco-transporter KCC2. Development 130, 1267-1280.
3. Bora E, Fornito A, Yücel M, Pantelis C (2010). Voxelwise meta-analysis of gray matter abnormalities in bipolar disorder. Biological Psychiatry 67, 1097-1105.
4. Boter H, Peuskens J, Libiger J, Fleischhacker WW, Davidson M, Galderisi S, Kahn RS; EUFEST study group (2009). Effectiveness of antipsychotics in first-episode schizophrenia and schizophreniform disorder on response and remission: an open randomized clinical trial (EUFEST). Schizophrenia Research 115, 97-103.
5. Cahn W, van Haren NEM, Hulshoff Pol HE, Schnack HG, Caspers E, Laponder DAJ, Kahn RS (2006). Brain volume changes in the first year of illness and 5-year outcome of schizophrenia. British Journal of Psychiatry 189, 381-382.
6. Carr V (2004). Are atypical antipsychotics advantageous? The case against. Australian Prescriber 27, 149-151.
7. Castillo-Gómez E, Gómez-Climent MA, Varea E, Guirado R, Blasco-Ibáñez JM, Crespo C, Martínez-Guijarro FJ, Nacher J (2008). Dopamine acting through D2 receptors modulates the expression of PSA-NCAM, a molecule related to neuronal structural plasticity, in the medial prefrontal cortex of adult rats. Experimental Neurology 214, 97-111.
8. Chiba S, Hashimoto R, Hattori S, Yohda M, Lipska B, Weinberger DR, Kunugi H (2006). Effect of antipsychotic drugs on DISC1 and dysbindin expression in mouse frontal cortex and hippocampus. Journal of Neural Transmission 113, 1337-1346.
9. Dazzan P, Morgan KD, Orr K, Hutchinson G, Chitnis X, Suckling J, Fearon P, McGuire PK, Mallett RM, Jones PB, Leff J, Murray RM (2005). Different effects of typical and atypical antipsychotics on grey matter in first episode psychosis: the ÆSOP study. Neuropsychopharmacology 30, 765-774.
10. Desikan RS, Ségonne F, Fischl B, Quinn BT, Dickerson BC, Blacker D, Buckner RL, Dale AM, Maguire RP, Hyman BT, Albert MS, Killiany RJ (2006). An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. Neuro Image 31, 968-980.
11. Dorph-Petersen K-A, Pierri JN, Perel JM, Sun Z, Sampson AR, Lewis DA (2005). The influence of chronic exposure to antipsychotic medications on brain size before and after tissue fixation: a comparison of haloperidol and olanzapine in macaque monkeys. Neuropsychopharmacology 30, 1649-1661.
12. Ellison-Wright I, Bullmore E (2010). Anatomy of bipolar disorder and schizophrenia: a meta-analysis. Schizophrenia Research 117, 1-12.
13. Fischl B, van der Kouwe A, Destrieux C, Halgren E, Ségonne F, Salat DH, Busa E, Seidman LJ, Goldstein J, Kennedy D, Caviness V, Makris N, Rosen B, Dale AM (2004). Automatically parcellating the human cerebral cortex. Cerebral Cortex 14, 11-22.
14. Fornito A, Yücel M, Wood SJ, Adamson C, Velakoulis D, Saling MM, McGorry PD, Pantelis C (2008). Surface-based morphometry of the anterior cingulate cortex in first episode schizophrenia. Human Brain Mapping 29, 478-489.
15. Garver DL, Holcomb JA, Christensen JD (2005). Cerebral cortical gray expansion associated with two second-generation antipsychotics. Biological Psychiatry 58, 62-66.
16. Girgis RR, Diwadkar VA, Nutche JJ, Sweeney JA, Keshavan MS, Hardan AY (2006). Risperidone in first-episode psychosis: a longitudinal, exploratory voxel-based morphometric study. Schizophrenia Research 82, 89-94.
17. González-Pinto A, Mosquera F, Palomino A, Alberich S, Gutiérrez A, Haidar K, Vega P, Barbeito S, Ortiz A, Matute C (2010). Increase in brain-derived neurotrophic factor in first episode psychotic patients after treatment with atypical antipsychotics. International Clinical Psychopharmacology 25, 241-245.
18. Gur RER, Cowell PP, Turetsky BIB, Gallacher FF, Cannon TT, Bilker WW, Gur RCR (1998). A follow-up magnetic resonance imaging study of schizophrenia. Relationship of neuroanatomical changes to clinical and neurobehavioral measures. Archives of General Psychiatry 55, 145-152.
19. Hagler DJ Jr., Saygin AP, Sereno MI (2006). Smoothing and cluster thresholding for cortical surface-based group analysis of fMRI data. Neuro Image 33, 1093-1103.
20. Harrison PJ (1999). The neuropathological effects of antipsychotic drugs. Schizophrenia Research 40, 87-99.
21. Ho B-C, Andreasen NC, Nopoulos P, Arndt S, Magnotta V, Flaum M (2003). Progressive structural brain abnormalities and their relationship to clinical outcome: a longitudinal magnetic resonance imaging study early in schizophrenia. Archives of General Psychiatry 60, 585-594.
22. Ho B-C, Andreasen NC, Ziebell S, Pierson R, Magnotta V (2011). Long-term antipsychotic treatment and brain volumes a longitudinal study of first-episode schizophrenia long-term antipsychotics and brain volumes. Archives of General Psychiatry 68, 128-137.
23. Janssen J, Reig S, Parellada M, Moreno D, Graell M, Fraguas D, Zabala A, Garcia Vazquez V, Desco M, Arango C (2008). Regional gray matter volume deficits in adolescents with first-episode psychosis. Journal of the American Academy of Child and Adolescent Psychiatry 47, 1311-1320.
24. Kahn RS, Fleischhacker WW, Boter H, Davidson M, Vergouwe Y, Keet IPM, Gheorghe MD, Rybakowski JK, Galderisi S, Libiger J, Hummer M, Dollfus S, López-Ibor JJ, Hranov LG, Gaebel W, Peuskens J, Lindefors N, Riecher-Rössler A, Grobbee DE; EUFEST study group (2008). Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 371, 1085-1097.
25. Kane JM (1996). Schizophrenia. New England Journal of Medicine 334, 34-41.
26. Kasai K, Shenton ME, Salisbury DF, Hirayasu Y, Onitsuka T, Spencer MH, Yurgelun-Todd DA, Kikinis R, Jolesz FA, McCarley RW (2003a). Progressive decrease of left Heschl gyrus and planum temporale gray matter volume in first-episode schizophrenia: a longitudinal magnetic resonance imaging study. Archives of General Psychiatry 60, 766-775.
27. Kasai K, Shenton ME, Salisbury DF, Onitsuka T, Toner SK, Yurgelun-Todd D, Kikinis R, Jolesz FA, McCarley RW (2003b). Differences and similarities in insular and temporal pole MRI gray matter volume abnormalities in first-episode schizophrenia and affective psychosis. Archives of General Psychiatry 60, 1069-1077.
28. Kay SR, Opler LA, Fiszbein A (1987). The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophrenia Bulletin 13, 261-276.
29. Koo MS, Levitt JJ, Salisbury DF, Nakamura M, Shenton ME, McCarley RW (2008). A cross-sectional and longitudinal magnetic resonance imaging study of cingulate gyrus gray matter volume abnormalities in first-episode schizophrenia and first-episode affective psychosis. Archives of General Psychiatry 65, 746-760.
30. Kuroki N, Shenton ME, Salisbury DF, Hirayasu Y, Onitsuka T, Ersner-Hershfield H, Yurgelun-Todd D, Kikinis R, Jolesz FA, McCarley RW (2006). Middle and inferior temporal gyrus gray matter volume abnormalities in first-episode schizophrenia: an MRI study. American Journal of Psychiatry 163, 2103-2110.
31. Lieberman JA, Tollefson GD, Charles C, Zipursky R, Sharma T, Kahn RS, Keefe RSE, Green AI, Gur RE, McEvoy J, Perkins D, Hamer RM, Gu H, Tohen M; HGDH Study Group (2005). Antipsychotic drug effects on brain morphology in first-episode psychosis. Archives of General Psychiatry 62, 361-370.
32. Lyoo IK, Dager SR, Kim JE, Yoon SJ, Friedman SD, Dunner DL, Renshaw PF (2010). Lithium-induced gray matter volume increase as a neural correlate of treatment response in bipolar disorder: a longitudinal brain imaging study. Neuropsychopharmacology 35, 1743-1750.
33. Maćkowiak M, Dudys D, Chocyk A, Wedzony K (2009). Repeated risperidone treatment increases the expression of NCAM and PSA-NCAM protein in the rat medial prefrontal cortex. European Neuropsychopharmacology 19, 125-137.
34. McClure RK, Carew K, Greeter S, Maushauer E, Steen G, Weinberger DR (2008). Absence of regional brain volume change in schizophrenia associated with short-term atypical antipsychotic treatment. Schizophrenia Research 98, 29-39.
35. McCormick L, Decker L, Nopoulos P, Ho BC, Andreasen N (2005). Effects of atypical and typical neuroleptics on anterior cingulate volume in schizophrenia. Schizophrenia Research 80, 73-84.
36. McGorry PD, Copolov DL, Singh BS (1990). Royal Park Multidiagnostic Instrument for Psychosis: Part I. Rationale and review. Schizophrenia Bulletin 16, 501-515.
37. Menezes NM, Arenovich T, Zipursky RB (2006). A systematic review of longitudinal outcome studies of first-episode psychosis. Psychological Medicine 36, 1349-1362.
38. Meyer-Lindenberg A (2011). Neuroimaging and the question of neurodegeneration in schizophrenia. Progress in Neurobiology 95, 514-516.
39. Miller DD, Andreasen NC, O'Leary DS, Watkins GL, Boles Ponto LL, Hichwa RD (2001). Comparison of the effects of risperidone and haloperidol on regional cerebral blood flow in schizophrenia. Biological Psychiatry 49, 704-715.
40. Molina V, Reig S, Sanz J, Palomo T, Benito C, Sánchez J, Sarramea F, Pascau J, Desco M (2005). Increase in gray matter and decrease in white matter volumes in the cortex during treatment with atypical neuroleptics in schizophrenia. Schizophrenia Research 80, 61-71.
41. Mondelli V, Anacker C, Vernon AC, Cattaneo A, Natesan S, Modo M, Dazzan P, Kapur S, Pariante CM (2013). Haloperidol and olanzapine mediate metabolic abnormalities through different molecular pathways. Translational Psychiatry 3, e208.
42. Morgan KD, Dazzan P, Orr KG, Hutchinson G, Chitnis X, Suckling J, Lythgoe D, Pollock S-J, Rossell S, Shapleske J, Fearon P, Morgan C, David A, McGuire PK, Jones PB, Leff J, Murray RM (2007). Grey matter abnormalities in first-episode schizophrenia and affective psychosis. British Journal of Psychiatry. Supplement 51, s111-s116.
43. Nakamura M, Salisbury DF, Hirayasu Y, Bouix S, Pohl KM, Yoshida T, Koo M-S, Shenton ME, McCarley RW (2007). Neocortical gray matter volume in first-episode schizophrenia and first-episode affective psychosis: a cross-sectional and longitudinal MRI study. Biological Psychiatry 62, 773-783.
44. Nelson HE, O'Connell A (1978). Dementia: the estimation of premorbid intelligence levels using the new adult reading test. Cortex 14, 234-244.
45. Noh JS, Kang HJ, Kim EY, Sohn S, Chung YK, Kim SU, Gwag BJ (2000). Haloperidol-induced neuronal apoptosis: role of p38 and c-Jun-NH(2)-terminal protein kinase. Journal of Neurochemistry 75, 2327-2334.
46. Pardo BM, Garolera M, Ariza M, Pareto D, Salamero M, Valles V, Delgado L, Alberni J (2011). Improvement of cognitive flexibility and cingulate blood flow correlates after atypical antipsychotic treatment in drug-naive patients with first-episode schizophrenia. Psychiatry Research 194, 205-211.
47. Rienke A, Martins MR, Lima MS, Moreira JC, Dal-Pizzol F, Quevedo J (2004). Haloperidol and clozapine, but not olanzapine, induces oxidative stress in rat brain. Neuroscience Letters 372, 157-160.
48. Selemon LD, Rajkowska G, Goldman-Rakic PS (1998). Elevated neuronal density in prefrontal area 46 in brains from schizophrenic patients: application of a three-dimensional, stereologic counting method. Journal of Comparative Neurology 392, 402-412.
49. Spitzer RL, Williams JB, Gibbon M, First MB (1992). The Structured Clinical Interview for DSM-III-R (SCID). I: History, rationale, and description. Archives of General Psychiatry 49, 624-629.
50. Takahashi T, Wood SJ, Soulsby B, Kawasaki Y, McGorry PD, Suzuki M, Velakoulis D, Pantelis C (2009a). An MRI study of the superior temporal subregions in first-episode patients with various psychotic disorders. Schizophrenia Research 113, 158-166.
51. Takahashi T, Wood SJ, Soulsby B, Tanino R, Wong MT, McGorry PD, Suzuki M, Velakoulis D, Pantelis C (2009b). Diagnostic specificity of the insular cortex abnormalities in first-episode psychotic disorders. Progress in Neuro-psychopharmacology and Biological Psychiatry 33, 651-657.
52. Tan Q-R, Wang X-Z, Wang C-Y, Liu X-J, Chen Y-C, Wang H-H, Zhang R-G, Zhen X-C, Tong Y, Zhang Z-J (2007). Differential effects of classical and atypical antipsychotic drugs on rotenone-induced neurotoxicity in PC12 cells. European Neuropsychopharmacology 17, 768-773.
53. Thompson PM, Bartzokis G, Hayashi KM, Klunder AD, Lu PH, Edwards N, Hong MS, Yu M, Geaga JA, Toga AW, Charles C, Perkins DO, McEvoy J, Hamer RM, Tohen M, Tollefson GD, Lieberman JA; the HGDH Study Group (2009). Time-lapse mapping of cortical changes in schizophrenia with different treatments. Cerebral Cortex 19, 1107-1123.
54. van Haren NE, Schnack HG, Cahn W, van den Heuvel MP, Lepage C, Collins L, Evans AC, Hulshoff Pol HE, Kahn RS (2011). Changes in cortical thickness during the course of illness in schizophrenia. Archives of General Psychiatry 68, 871-880.
55. Velakoulis D, Pantelis C, McGorry PD, Dudgeon P, Brewer W, Cook M, Desmond P, Bridle N, Tierney P, Murrie V, Singh B, Copolov D (1999). Hippocampal volume in first-episode psychoses and chronic schizophrenia: a high-resolution magnetic resonance imaging study. Archives of General Psychiatry 56, 133-141.
56. Velakoulis D, Wood SJ, Wong MTH, McGorry PD, Yung A, Phillips L, Smith D, Brewer W, Proffitt T, Desmond P, Pantelis C (2006). Hippocampal and amygdala volumes according to psychosis stage and diagnosis: a magnetic resonance imaging study of chronic schizophrenia, first-episode psychosis, and ultra-high-risk individuals. Archives of General Psychiatry 63, 139-149.
57. Vernon AC, Crum WR, Lerch JP, Chege W, Natesan S, Modo M, Cooper JD, Williams SC, Kapur S (2014). Reduced cortical volume and elevated astrocyte density in rats chronically treated with antipsychotic drugs - linking magnetic resonance imaging findings to cellular pathology. Biological Psychiatry 75, 982-990.
58. Vernon AC, Natesan S, Modo M, Kapur S (2011). Effect of chronic antipsychotic treatment on brain structure: a serial magnetic resonance imaging study with ex vivo and postmortem confirmation. Biological Psychiatry 69, 936-944.
59. Walterfang M, Wood AG, Reutens DC, Wood SJ, Chen J, Velakoulis D, McGorry PD, Pantelis C (2009). Corpus callosum size and shape in first-episode affective and schizophrenia-spectrum psychosis. Psychiatry Research 173, 77-82.
60. Weinberger DR, McClure RK (2002). Neurotoxicity, neuroplasticity, and magnetic resonance imaging morphometry: what is happening in the schizophrenic brain? Archives of General Psychiatry 59, 553-558.
61. Wiegand LC, Warfield SK, Levitt JJ, Hirayasu Y, Salisbury DF, Heckers S, Dickey CC, Kikinis R, Jolesz FA, McCarley RW, Shenton ME (2004). Prefrontal cortical thickness in first-episode psychosis: a magnetic resonance imaging study. Biological Psychiatry 55, 131-140.
62. Wood SJ, Berger GE, Lambert M, Conus P, Velakoulis D, Stuart GW, Desmond P, McGorry PD, Pantelis C (2006). Prediction of functional outcome 18 months after a first psychotic episode: a proton magnetic resonance spectroscopy study. Archives of General Psychiatry 63, 969-976.
63. Woods SW (2003). Chlorpromazine equivalent doses for the newer atypical antipsychotics. Journal of Clinical Psychiatry 64, 663-667.
64. Zipursky RB, Reilly TJ, Murray RM (2013). The myth of schizophrenia as a progressive brain disease. Schizophrenia Bulletin 39, 1363-1372.